We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




POC D-Dimer Assays Compared with Standard Method

By LabMedica International staff writers
Posted on 18 Apr 2012
D-dimer assays are effective for the exclusion of deep-vein thrombosis (DVT), but point-of-care (POC) D-dimer assays have only recently been fully evaluated.

Measurement of D-dimer has been enabled after the development of monoclonal antibodies used in enzyme-linked immunosorbent assays (ELISAs) which have a sensitivity of 98% with a negative predictive value of greater than 95%. More...


However, ELISAs are complicated, time-consuming, and labor intensive and could generally only be performed in laboratories during daytime working hours. Scientists at the Karolinska Institutet, (Stockholm, Sweden) compared five POC D-dimer assays with their routine Tinaquant fully automated quantitative immunoturbidimetric assay that utilizes microlatex particles coated with anti-human D-dimer monoclonal antibody. They tested 60 samples from patients with suspected DVT. The cut-off value was 0.25 µg/mL of D-dimer, which corresponds to 0.5 µg/mL of fibrinogen equivalent units (FEU).

The five POC assays tested were the Pathfast D-dimer chemiluminescent enzyme immunoassay (CLEIA) magnetic filtration (Mitsubishi Chemical; Tokyo, Japan); the Cardiac D-dimer sandwich method, using monoclonal gold-labeled antibodies which like the standard Tinaquant assay is from Roche Diagnostics, (Mannheim, Germany); the Vidas D-dimer, a sandwich method, using monoclonal antibodies with fluorescence detection (BioMérieux; Marcy l’Etoile, France); the Stratus CS D-dimer sandwich method using monoclonal antibodies radial partition (Siemens Diagnostics; Marburg, Germany); and the NycoCard D-dimer sandwich method, which uses monoclonal antibodies gold colloids (Nycomed Pharma; Oslo, Norway).

The results of the study showed that using 0.5 µg/mL as a cut-off value, four samples tested negative with Tinaquant were positive with Pathfast. There were no Tinaquant-positive samples tested negative with Pathfast, while the overall agreement was very good. Four samples were discrepant between Tinaquant and Cardiac with the lower cut-off of 0.4 µg/mL. Eight samples of 27 were negative with NycoCard although they were positive with the standard Tinaquant assay. The agreement with Tinaquant was excellent for both Vidas and Stratus.

The authors concluded that that the four of five tested POC D-dimer assays have an analytical profile comparable to that obtained using standard laboratory assay, while three of them may be used for rapid bed-side analysis. Their evaluation indicates that Pathfast D-dimer, Cardiac D-dimer and Stratus CS D-dimer can be used for rapid bed-side analysis and offers a possibility to adequately rule out DVT in outpatients within minutes after admission. The study was published on April 5, 2012, in the International Journal of Laboratory Hematology.

Related Links:

Karolinska Institutet
Mitsubishi Chemical
Roche Diagnostics




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.